

Human PIGF



www.mesoscale.com®

Ordering Information

MSD Customer Service Phone: 1-240-314-2795 Fax: 1-301-990-2776 Email: CustomerService@ mesoscale.com

Scientific Support

Phone: 1-240-314-2798 Email: ScientificSupport@ mesoscale.com


Company Address

Meso Scale Discovery A division of Meso Scale Diagnostics, LLC. 1601 Research Boulevard Rockville, MD 20850-3173 USA

Product Options	Catalog Number	Description	
Multiplex	K151AEM, K251AEM	U-PLEX Immuno-Oncology Group 1 (human)	
Singleplex	K151B8K-1/-2/-4	U-PLEX Human PIGF Assay with SECTOR™ plates	
	K151B8K-21/-22/-24	U-PLEX Human PIGF Assay with QuickPlex Ultra™ plates	
	K251B8K-2/-4	U-PLEX Human PIGF Assay with 384-well plates	
Antibody Set	B22B8-2/-3	U-PLEX Human PIGF Antibody Set	
Protocol	U-PLEX Product Inserts are available at www.mesoscale.com		

The MESO SCALE DISCOVERY® U-PLEX platform was designed to provide ultimate flexibility for detection of biomarkers in a wide variety of sample types. This datasheet provides the representative performance of the U-PLEX® Human PIGF Assay tested on U-PLEX 96-well SECTOR plates run as a multiplex. The data do not represent the product specifications. Under your experimental conditions, the assay may perform differently from the representative data. U-PLEX assays are offered in either singleplex or multiplex; both are available on 96- or 384-well plates. See a U-PLEX product insert for instrument compatibility.

Representative Calibration Curve and Sensitivity



Assay	Median LLOD (pg/mL)	LLOD Range (pg/mL)	
PIGF	0.19	0.06-0.49	


The Calibrator curve was fitted with a 4-parameter logistic model with a $1/Y^2$ weighting. The lower limit of detection (LLOD) is a calculated concentration corresponding to 2.5 standard deviations above the background (zero Calibrator).

Precision

Control	Average Conc. (pg/mL)	Average Intra-run Conc. (%CV)	Inter-run Conc. (%CV)
High	49	3.0	12.8
Mid	21	4.0	15.2
Low	7.9	4.8	18.0

Controls were made by spiking Calibrator into assay diluent at 3 levels within the quantitative range of the assay. Average intra-run concentration %CV is the average %CV of the control replicates within an individual run. Inter-run concentration %CV is the variability of controls across multiple runs.

For Research Use Only. Not for use in diagnostic procedures.





MSD® U-PLEX Human PIGF

Tested Samples

Sample Type	Serum (N=10)	EDTA Plasma (N=10)	Normal Lysate (N=5)	Tumor Lysate (N=5)
Median (pg/mL)	6.4	5.8	3.4	3.9
Range (pg/mL)	6.0-7.5	3.8-8.1	1.1-11	028-89
% Detected	100	100	100	100

Normal serum and plasma samples were diluted 4-fold prior to the assay. Lysates were tested at a protein concentration of 0.5 mg/mL.

Dilution Linearity

Serum			EDTA Plasma		
Fold Dilution		Fold Dilution	Average % Recovery	% Recovery Range	
2	95	93 - 99	2	95	90 - 102
8	100	99 - 102	8	100	97 - 101
16	101	98 - 105	16	96	89 - 101

Normal human serum and EDTA plasma were spiked with Calibrator and tested at different dilutions. Percent recovery at each dilution level was normalized to the dilutionadjusted, 4-fold concentration. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

% Recovery = (measured concentration / expected concentration) x 100

Spike Recovery

	Ser	um	EDTA Plasma	
Spike Level	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range
High	82	79 - 89	84	77 - 90
Mid	77	59 - 86	89	84 - 92
Low	97	85 - 124	92	83 - 98

Normal serum and plasma were spiked with Calibrator at 3 levels. Spiked samples were diluted 4-fold to determine the expected concentration of the analyte. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

% Recovery = (measured concentration / expected concentration) x 100

Specificity

To assess specificity, the PIGF Antibody Set was tested individually against a larger panel of analytes for nonspecific binding: APRIL/TNFSF13, BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD276/B7-H3, CD28, CD40L (soluble), CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FLT3L, Fractalkine, G-CSF, Galectin-9, GITR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO- α , HAVCR2/TIM-3, HVEM/TNFRSF14, I-309, ICOS, ICOSL/B7-H2, IFN- α 2a, IFN- β , IFN- γ , IL-1 α , IL-1 β , IL-1RA, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN- α 1, IL-2R α 1, IL-33, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IP-10, I-TAC, LAG-3, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1 α 1, MIP-5, MMP-1, MMP-2, MMP-7, MMP-9, Nectin-4, OX40/TNFRSF4, PD1, PD-L1, PD-L2, Pentraxin 3, Perforin, PIGF, P-Selectin, RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, SDF-1 α 1, TARC, Tie-2, TIGIT, TLR-1, TNF-RI, TNF-RI, TNF-RI, TNF- α 5, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/FIt-1 and YKL-40. Nonspecific binding was less than 2.0%.

% Nonspecificity = (nonspecific signal / specific signal) x 100

Diluent Compatibility

Diluents 58 and 3 are provided with this assay. MSD offers a range of assay and antibody diluents for separate purchase. Depending on your assay needs, other diluents may be tested.

Assay Components

Calibrator: PIGF is included in Calibrator 21. The human PIGF Calibrator is PIGF (21-149) expressed in a bacteria.

Antibodies: The U-PLEX Human PIGF Assay uses a mouse monoclonal antibody for capture and a mouse monoclonal antibody for detection.

Assay generation: B

Note: This datasheet contains representative assay performance data. In custom multiplex formats, the assay may perform differently from the representative data shown.



MESO SCALE DISCOVERY, MESO SCALE DIAGNOSTICS, www.mesoscale.com, MSD, MSD (design), QuickPlex Ultra, SECTOR, U-PLEX, U-PLEX (design), 96 WELL SMALL-SPOT (design), and Spot the Difference are trademarks and/or service marks of Meso Scale Diagnostics, LLC.

©2016-2025 Meso Scale Diagnostics, LLC. All rights reserved.